( MENAFN - GlobeNewsWire - Nasdaq) NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
(Nasdaq: NAMS or“NewAmsterdam” or the“Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 – 21, 2024 in London. Details are as follows: 2024 AHA Scientific Sessions Presentation Title: Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN) Session Title: Late-Breaking Science 8: New Targets and New Treatments: Advances in Lipid Therapeutics Presentation Date and Time: Monday, November 18, 2024, 2:14 p.
m. – 2:26 p.m.
CST (3:14 p.m. – 3:26 p.
m. ET) Presenter: Stephen Nicholls, M.B.
B.S., Ph.
D., Director, Monash Victorian Heart Institute .